A Phase I/II Clinical Trial of RC1012 Injection for the Prevention of Relapse in AML Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Latest Information Update: 23 May 2023
At a glance
- Drugs RC-1012 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors WYZE Biotech
Most Recent Events
- 17 May 2023 Status changed from active, no longer recruiting to recruiting.
- 17 May 2023 New trial record